SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-001432
Filing Date
2022-01-18
Accepted
2022-01-18 09:30:13
Documents
12
Period of Report
2022-01-13
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 32528
  Complete submission text file 0001493152-22-001432.txt   203423

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qlgn-20220113.xsd EX-101.SCH 3042
3 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qlgn-20220113_lab.xml EX-101.LAB 34476
4 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qlgn-20220113_pre.xml EX-101.PRE 22601
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3499
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

IRS No.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37428 | Film No.: 22533887
SIC: 2834 Pharmaceutical Preparations